Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: neural regeneration peptides - CuroNZ

Drug Profile

Research programme: neural regeneration peptides - CuroNZ

Alternative Names: Neuro-regenerative peptides; Neuronal regeneration peptides; NNZ-4921; NRPs programme

Latest Information Update: 27 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Metabolic Pharmaceuticals; Neuren Pharmaceuticals
  • Developer CuroNZ
  • Class Nerve growth factors; Neuropeptides
  • Mechanism of Action Cell differentiation stimulants; CXCR4 receptor modulators; Neuron stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Amyotrophic lateral sclerosis; Multiple sclerosis; Peripheral nervous system diseases; Retinal disorders; Stroke
  • Discontinued Spinal cord injuries

Most Recent Events

  • 27 Nov 2017 Preclinical development for Amyotrophic lateral sclerosis, Multiple sclerosis, Peripheral nervous system diseases, Retinal disorders and Stroke is ongoing in New Zeland (CuroNZ website, November 2017)
  • 27 Nov 2017 Discontinued - Preclinical for Spinal cord injuries in New Zealand (Parenteral)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Amyotrophic-lateral-sclerosis in New Zealand (Parenteral, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top